6533b856fe1ef96bd12b2fb8

RESEARCH PRODUCT

Additional file 6: Figure S4. of Serum metabolites in non-alcoholic fatty-liver disease development or reversion; a targeted metabolomic approach within the PREDIMED trial

Christopher PapandreouMònica BullòFrancisco TinahonesMiguel Martínez-gonzálezDolores CorellaGeorgios FragkiadakisJosé López-mirandaRamon EstruchMontserrat FitóJordi Salas-salvadó

subject

description

Principal component analysis (PCA) to discriminate between the baseline and final states in group 3 (suspected NAFLD reversion cases). Model diagnostics (A = 6, R2X = 0.628, Q2X = 0.235) (DOCX 42 kb)

https://dx.doi.org/10.6084/m9.figshare.c.3870565_d8